Biologics prompt exclusivity debate

By Doug Wong

St. Louis Post-Dispatch

BY ANDREW POLLACK

New York Times

A bitter congressional fight over the cost of super-expensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?

But what few people…

Tags: biotech, generic drugs, medicine, pharmaceuticals

Comments Off
Email this